Zhejiang Jingxin Pharmaceutical's (SZSE:002020) Problems Go Beyond Weak Profit

The subdued market reaction suggests that Zhejiang Jingxin Pharmaceutical Co., Ltd.'s (SZSE:002020) recent earnings didn't contain any surprises. We think that investors are worried about some weaknesses underlying the earnings.

View our latest analysis for Zhejiang Jingxin Pharmaceutical

How Do Unusual Items Influence Profit?

For anyone who wants to understand Zhejiang Jingxin Pharmaceutical's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥67m worth of unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. Assuming those unusual items don't show up again in the current year, we'd thus expect profit to be weaker next year (in the absence of business growth, that is).

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Zhejiang Jingxin Pharmaceutical's Profit Performance

Arguably, Zhejiang Jingxin Pharmaceutical's statutory earnings have been distorted by unusual items boosting profit. Therefore, it seems possible to us that Zhejiang Jingxin Pharmaceutical's true underlying earnings power is actually less than its statutory profit. In further bad news, its earnings per share decreased in the last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. If you'd like to know more about Zhejiang Jingxin Pharmaceutical as a business, it's important to be aware of any risks it's facing. Case in point: We've spotted 1 warning sign for Zhejiang Jingxin Pharmaceutical you should be aware of.

This note has only looked at a single factor that sheds light on the nature of Zhejiang Jingxin Pharmaceutical's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.